Zomedica CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Zomedica Corp. reported a 17% increase in revenue to $32.03 million for fiscal year 2025, alongside a significant net loss of $81.86 million driven by impairment charges following its delisting from NYSE American.
Zomedica Corp.'s 2024 10-K filing reveals a company in transition, navigating delisting from NYSE American while focusing on strategic acquisitions and product commercialization to drive future growth.
Zomedica Corp.'s 10-K filing highlights a year of strategic acquisitions and revenue growth, alongside ongoing losses and a focus on expanding its veterinary product portfolio.